Capricor Therapeutics' Deramiocel shows efficacy in Phase III Duchenne muscular dystrophy trial

Phase III clinical trial results published in The Lancet indicate that Deramiocel successfully slows muscle deterioration in patients with Duchenne muscular dystrophy. While the data demonstrates clinical efficacy, the long-term durability of the therapy and regulatory approval timelines remain to be determined.